Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2, 2023.
For additional information or to request a meeting with management, please contact conference representatives.
About Inversago Pharma
Inversago Pharma is a privately owned, clinical stage, Canadian biotech company, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005328/en/
Glenn S. Vraniak
Chief Financial Officer
Inversago Pharma Inc.
Media and Investors
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Palantir Awarded Australian Transaction Reports and Analysis Centre (AUSTRAC) Renewal to Support Financial Criminal Investigations23.3.2023 23:18:00 EET | Press release
Palantir Technologies Inc. (NYSE: PLTR) today announced that the Australian Transaction Reports and Analysis Centre (AUSTRAC) renewed its partnership for the ongoing delivery of an intelligence data analysis platform to support the AUSTRAC mission of protecting Australia’s financial system from criminal abuse. Since 2017, Palantir has partnered with AUSTRAC to optimise their use of financial data in support of criminal investigations. AUSTRAC builds resilience in the financial system and uses financial intelligence and regulation to disrupt money laundering, terrorism financing, and other serious crime. AUSTRAC utilizes Palantir Technologies’ Gotham and Foundry software platforms to integrate and fuse large scale data across their enterprise, driving decisions and operational outcomes. “We are proud to continue and expand our partnership with AUSTRAC and remain firmly committed to supporting their mission,” said Mike Kelly, Head of Palantir Australia. “AUSTRAC personnel are using Palan
Interactive Brokers Expected to Raise Interest Rates to USD 4.33% on Instantly Available Cash23.3.2023 20:59:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that clients are expected to earn up to USD 4.33% on instantly available cash balances over USD 10,000. Unlike brokerages that offer significantly lower rates, Interactive Brokers conveniently pays interest directly to client brokerage accounts. This eliminates the need for separate sweeps accounts, funds or programs and enables cash to be instantly available. While interest rates available at other brokerages are only USD 0.01% – 2.32%, the market interest paid by Interactive Brokers, is calculated using the Fed Funds rate as the reference rate for USD minus 0.5%. As a result, if interest rates continue to rise as expected, clients of Interactive Brokers will have the opportunity to earn more. “In the current rising rate environment, many investors are considering how to earn more in their brokerage and savings accounts,” said Thomas Peterffy, Founder and Chairman of Interactive Brokers. “Invest
DENZA Partners with DEVIALET on Car Audio System23.3.2023 20:00:00 EET | Press release
On 22nd March 2023, the DENZA x DEVIALET Cooperation Kick-off Evening was held at the Bay Opera of Shenzhen. DENZA and DEVIALET jointly unveiled the DENZA N7, the world's first mass-produced model coming with the DEVIALET car audio system. This cooperation witnesses DENZA become the first brand to apply DEVIALET’s audio system and serves as a paradigm of international cooperation in the global automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005522/en/ DENZA x DEVIALET Cooperation Kick-off Evening (Photo: Business Wire) Zhao Changjiang, General Manager of DENZA, said: “High-quality music brings users enjoyment of life, and intelligent music cockpit is the standard element for the new luxury.” Franck Lebouchard, CEO of DEVIALET, commented, “This is a collaboration between two market leaders with a mission to redefine sound experiences in mobility. Our partnership with DENZA marks a partnership conclud
Lunaphore Raises CHF 40M in the First Close of Series D Funding led by EGS Beteiligungen AG23.3.2023 18:03:00 EET | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced today that it has completed CHF 40M in Series D1 funding. The round was led by Ernst-Göhner Stiftung Beteiligungen (EGSB) and existing investors PHC Holdings Corporation, Swiss Entrepreneurs Fund, OCCIDENT, and Redalpine participated. The funding includes a EUR 10M venture debt facility provided by Norgine Ventures. The company plans to use the funding to strengthen its growing portfolio offering in spatial biology as well as support commercial execution to address ever-growing demand from customers. “We are thrilled to have such a highly regarded name like EGSB among our investors. EGSB has an excellent track record of supporting rapidly growing portfolio companies beyond $100M in revenues. In addition, the debt facility from Norgine Ventures will help us to invest in scaling our company even faster,” said Ata Tuna Ciftlik, CEO of Lunaphore. “The funding comes in a m
Ionblox Appoints Dr. Shirley Meng to Advisory Board23.3.2023 18:00:00 EET | Press release
Ionblox, a California-based, advanced lithium-ion battery company, has appointed Dr. Shirley Meng of the University of Chicago to their advisory board. Dr. Meng is a Professor of Molecular Engineering at the University of Chicago as well as the Chief Scientist for Argonne Collaborative Center for Energy Storage Science (ACCESS), and holds a Ph.D. in Advanced Materials for Micro and Nano Systems. “I look forward to working with the Ionblox team to commercialize their high-performance lithium-ion batteries using a pre-lithiated silicon oxide anode,” said Dr. Meng. “Ionblox is unique in applying a pre-lithiation strategy to their electrode design which is critical for improving the performance and durability of their silicon-based cells.” At her current positions, Dr. Meng focuses her research on energy storage materials and systems, specifically on rechargeable batteries for electric vehicles, power sources for Internet of Things (IOTs) and sustainable grid-scale storage. Dr. Meng founde
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom